BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 37812756)

  • 1. Management of Metastatic Renal Clear Cell Cancer: ASCO Guideline Rapid Recommendation Update.
    Singer EA; Rumble RB; Rathmell WK; Van Veldhuizen PJ;
    J Clin Oncol; 2023 Nov; 41(33):5184-5186. PubMed ID: 37812756
    [No Abstract]   [Full Text] [Related]  

  • 2. Cancer Cachexia: ASCO Guideline Rapid Recommendation Update.
    Roeland EJ; Bohlke K; Baracos VE; Smith TJ; Loprinzi CL;
    J Clin Oncol; 2023 Sep; 41(25):4178-4179. PubMed ID: 37467399
    [No Abstract]   [Full Text] [Related]  

  • 3. Management of Stage III Non-Small-Cell Lung Cancer: ASCO Guideline Rapid Recommendation Update.
    Singh N; Daly ME; Ismaila N;
    J Clin Oncol; 2023 Sep; 41(27):4430-4432. PubMed ID: 37471673
    [No Abstract]   [Full Text] [Related]  

  • 4. Systemic Therapy Update on
    Garje R; Rumble RB; Parikh RA;
    J Clin Oncol; 2023 Nov; ():JCO2302128. PubMed ID: 37931186
    [No Abstract]   [Full Text] [Related]  

  • 5. Testing for
    Burstein HJ; DeMichele A; Somerfield MR; Henry NL;
    J Clin Oncol; 2023 Jun; 41(18):3423-3425. PubMed ID: 37196213
    [No Abstract]   [Full Text] [Related]  

  • 6. Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer-Cyclin-Dependent Kinase 4 and 6 Inhibitors: ASCO Guideline Rapid Recommendation Update.
    Freedman RA; Caswell-Jin JL; Hassett M; Somerfield MR; Giordano SH;
    J Clin Oncol; 2024 Jun; 42(18):2233-2235. PubMed ID: 38768407
    [No Abstract]   [Full Text] [Related]  

  • 7. Endocrine and Targeted Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer-Capivasertib-Fulvestrant: ASCO Rapid Recommendation Update.
    Burstein HJ; DeMichele A; Fallowfield L; Somerfield MR; Henry NL; ;
    J Clin Oncol; 2024 Apr; 42(12):1450-1453. PubMed ID: 38478799
    [No Abstract]   [Full Text] [Related]  

  • 8. Systemic Therapy for Melanoma: ASCO Guideline Rapid Recommendation Update.
    Seth R; Messersmith H; Funchain P;
    J Clin Oncol; 2022 Jul; 40(21):2375-2377. PubMed ID: 35658488
    [No Abstract]   [Full Text] [Related]  

  • 9. Management and Care of Patients With Invasive Cervical Cancer: ASCO Resource-Stratified Guideline Rapid Recommendation Update.
    Chuang LT; Temin S; Berek JS;
    JCO Glob Oncol; 2022 Mar; 8():e2200027. PubMed ID: 35245079
    [No Abstract]   [Full Text] [Related]  

  • 10. Poly(ADP-Ribose) Polymerase Inhibitors in the Management of Ovarian Cancer: ASCO Guideline Rapid Recommendation Update.
    Tew WP; Lacchetti C; Kohn EC;
    J Clin Oncol; 2022 Nov; 40(33):3878-3881. PubMed ID: 36150092
    [No Abstract]   [Full Text] [Related]  

  • 11. Chemotherapy and Targeted Therapy for Endocrine-Pretreated or Hormone Receptor-Negative Metastatic Breast Cancer: ASCO Guideline Rapid Recommendation Update.
    Moy B; Rumble RB; Carey LA;
    J Clin Oncol; 2023 Feb; 41(6):1318-1320. PubMed ID: 36626701
    [No Abstract]   [Full Text] [Related]  

  • 12. Systemic Therapy Update on
    Garje R; Rumble RB; Parikh RA
    J Clin Oncol; 2022 Nov; 40(31):3664-3666. PubMed ID: 36112960
    [No Abstract]   [Full Text] [Related]  

  • 13. Chemotherapy and Targeted Therapy for Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer That Is Either Endocrine-Pretreated or Hormone Receptor-Negative: ASCO Guideline Rapid Recommendation Update.
    Moy B; Rumble RB; Carey LA;
    J Clin Oncol; 2022 Sep; 40(26):3088-3090. PubMed ID: 35926153
    [No Abstract]   [Full Text] [Related]  

  • 14. Use of Immune Checkpoint Inhibitor Pembrolizumab in the Treatment of High-Risk, Early-Stage Triple-Negative Breast Cancer: ASCO Guideline Rapid Recommendation Update.
    Korde LA; Somerfield MR; Hershman DL;
    J Clin Oncol; 2022 May; 40(15):1696-1698. PubMed ID: 35417251
    [No Abstract]   [Full Text] [Related]  

  • 15. Adjuvant Systemic Therapy and Adjuvant Radiation Therapy for Stage I-IIIA Completely Resected Non-Small-Cell Lung Cancer: ASCO Guideline Rapid Recommendation Update.
    Pisters K; Kris MG; Gaspar LE; Ismaila N;
    J Clin Oncol; 2022 Apr; 40(10):1127-1129. PubMed ID: 35167335
    [No Abstract]   [Full Text] [Related]  

  • 16. Immunotherapy in Patients With Locally Advanced Esophageal Carcinoma: ASCO Treatment of Locally Advanced Esophageal Carcinoma Guideline Rapid Recommendation Update.
    Shah MA; Hofstetter WL; Kennedy EB;
    J Clin Oncol; 2021 Oct; 39(28):3182-3184. PubMed ID: 34406872
    [No Abstract]   [Full Text] [Related]  

  • 17. Adjuvant PARP Inhibitors in Patients With High-Risk Early-Stage HER2-Negative Breast Cancer and Germline
    Tung NM; Zakalik D; Somerfield MR;
    J Clin Oncol; 2021 Sep; 39(26):2959-2961. PubMed ID: 34343058
    [No Abstract]   [Full Text] [Related]  

  • 18. Abemaciclib With Endocrine Therapy in the Treatment of High-Risk Early Breast Cancer: ASCO Optimal Adjuvant Chemotherapy and Targeted Therapy Guideline Rapid Recommendation Update.
    Giordano SH; Freedman RA; Somerfield MR;
    J Clin Oncol; 2022 Jan; 40(3):307-309. PubMed ID: 34878801
    [No Abstract]   [Full Text] [Related]  

  • 19. Therapy for Stage IV Non-Small-Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2022.3.
    Jaiyesimi IA; Owen DH; Ismaila N; Blanchard E; Celano P; Florez N; Jain D; Singh N
    J Clin Oncol; 2023 Apr; 41(11):e31-e41. PubMed ID: 36802359
    [No Abstract]   [Full Text] [Related]  

  • 20. Therapy for Stage IV Non-Small-Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2023.1.
    Singh N; Jaiyesimi IA; Ismaila N; Leighl NB; Mamdani H; Phillips T; Owen DH
    J Clin Oncol; 2023 May; 41(15):e42-e50. PubMed ID: 37023367
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.